A study to compare the effect of SB3 and Herceptin® in women with Breast Cancer The primary objective of this study is to demonstrate comparable clinical efficacy of SB3 to Herceptin®, in terms of Pathologic complete response rate of the primary breast tumour in women with HER2 p...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study Comparing SB2 to Remicade® in Subjects with Moderate to Severe Rheumatoid Arthritis The primary objective of this study is to demonstrate the equivalence of SB2 to Remicade at Week 30, in terms of the American College of Rheumatology 20% response criteria (ACR20) response rate in sub...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long-term Follow-up Study for Cardiac Safety in the Patients with Breast Cancer Who Have Completed the Main Study The primary objective is to observe the incidence of symptomatic congestive heart failure (CHF) NYHA class II,III and IV and asymptomatic LVEF decrease in patients who participated in the SB3-G31-BC S...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study Comparing SB4 to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy The primary objective of this study is to demonstrate the equivalence of SB4 to Enbrel® at Week 24, in terms of American College of Rheumatology 20% response criteria (ACR 20) response rate in subject...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study Comparing SB5 to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy The primary objective of this study is to demonstrate the equivalence of SB5 to Humira® atWeek 24, in terms of American College of Rheumatology 20% response criteria (ACR20) response rate in subjects ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study Comparing SB8 to Avastin in Subjects with Lung Cancer (Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer) To demonstrate the equivalence of SB8 to Avastin®, in terms of the best overall response rate (ORR) by 24 weeks of chemotherapy in subjects with metastatic or recurrent non squamous NSCLC.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

SB3-G31-BC : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité, la tolérance, la pharmacocinétique et l’immunogénicité du SB3 (proche du trastuzumab) et du trastuzumab (Herceptine®), chez des patientes ayant un cancer du sein HER2+. [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance d’un traitement néoadjuvant par du trastuzumab ou du SB3 (proche du trastuzumab), chez des patientes ayant un cancer du sein HER2+ no...

• Pays France
• Organes Sein
• Spécialités Thérapies Ciblées